Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study - 01/02/21
Doi : 10.1016/j.jaci.2020.12.529
Lawrence Eichenfield 1, Carsten Flohr 2, Robert Sidbury 3, Zsuzsanna Szalai 4, Ryszard Galus 5, Zhirong Yao 6, Hidetoshi Takahashi 7, Sébastien Barbarot 8, Claire Feeney 9, Fan Zhang 10, Marco DiBonaventura 10, Ricardo Rojo 10, Hernan Valdez 10, Gary Chan 10
1 UC San Diego
2 St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, King's College London
3 Seattle Children's Hospital
4 Heim Pál Children's Hospital
5 Medical University of Warsaw
6 Xinhua Hospital, Shanghai Jiaotong University School of Medicine
7 Takagi Dermatological Clinic
8 CHU Hôtel-Dieu
9 Pfizer Ltd.
10 Pfizer Inc
467
Il testo completo di questo articolo è disponibile in PDF.Mappa
© 2020
Pubblicato da Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB146 - Febbraio 2021 Ritorno al numero
Articolo precedente
- Safety and Outcomes for Penicillin Skin Testing in Pregnancy
- Vima Patel, Olajumoke Fadugba, Steven Ralston, Kathryn Delaney, Scott Feldman
- Application of a Physiologically Based Modeling to Increase the Knowledge on Epinephrine Absorption from A Novel Nasal Spray (ARS-1) In Healthy Adults
- Jeff Barrett
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?